As the Trump administration seeks to fast-track psychedelic drugs, the FDA could approve one for the first time early next year. But that possibility has brought up complicated questions about who should be allowed to administer the treatments and under what conditions.
FOR SUBSCRIBERSThis voting bloc holds the key to the midterms
FOR SUBSCRIBERSLatino voters feel buyer’s remorse in battleground Texas
FOR SUBSCRIBERSWhat’s on the Supreme Court’s docket this term?
FOR SUBSCRIBERSThis voting bloc holds the key to the midterms
FOR SUBSCRIBERSLatino voters feel buyer’s remorse in battleground Texas
FOR SUBSCRIBERSWhat’s on the Supreme Court’s docket this term?
Just a moment.
We are getting your experience ready.














